Piper Sandler analyst Yasmeen Rahimi raised the firm’s price target on Soleno Therapeutics (SLNO) to $145 from $93 and keeps an Overweight rating on the shares. Following VYKAT XR approval, the firm has received increasing investor inbounds, where feedback is positive on the spot clean label and confidence in management’s ability to launch. Into the Q1 update, management will share preliminary start form data. Piper believes Soleno is one of the most noteworthy names in this challenging market.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics announces VYKAT XR launch
- Soleno Therapeutics put volume heavy and directionally bearish
- Positive Outlook for Soleno Therapeutics Following FDA Approval and Strong Financial Position
- Soleno Therapeutics price target raised to $100 from $70 at H.C. Wainwright
- Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue